Mixed manic depressive episode

Also known as: Acute mixed episode / Bipolar affective disorder, mixed / Mixed episodes / Mixed episode / Mixed bipolar affective disorder / Bipolar affective disorder, mixed, unspecified degree / Bipolar I disorder

DrugDrug NameDrug Description
DB01238AripiprazoleAripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's[Label]. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania[Label]. Aripiprazole exerts its effects through agonism of dopaminic and 5-HT1A receptors and antagonism of alpha adrenergic and 5-HT2A receptors[Label,A4393]. Aripiprazole was given FDA approval on November 15, 2002[L6136].
DB06216AsenapineDeveloped by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
DB00564CarbamazepineAn anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar.
DB06016CariprazineCariprazine is an antipsychotic drug developed by Gedeon Richter and marketed by Actavis under the trade name Vraylar. Cariprazine acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. This mechanism is relatively unique, since many other antipsychotics are D2 and 5-HT2A agonists. Cariprazine was approved by the FDA in September 2015 and is indicated in the treatment of schizophrenia and bipolar disorder. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder.
DB01068ClonazepamA benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop [FDA Label] [L5572, F3763, F3787, F3796]. The agent has also been indicated for treating panic disorder [FDA Label] [A175438, L5572, F3763, F3787, F3796]. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses [FDA Label] [A175438, A175441, L5572, F3763, F3787, F3796]. Since being first patented in 1960 and then released for sale from Roche in the US in 1975 [T469, T472], clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse [FDA Label] [L5572, F3763, F3787, F3796].
DB00334OlanzapineOlanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent.[A176996] The second-generation antipsychotics were introduced in the 90s and quickly widespread due to the presumed higher efficacy, less extrapyramidal side effects and fewer drug-drug interactions.[A177011] Olanzapine presents a very close resemblance to [clozapine] and it only differs by two additional methyl groups and the absence of a chloride moiety.[T554] It was obtained by the research of Eli Lilly and approved to be marketed in the US in 1996.[T548]
DB01224QuetiapineQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
DB00734RisperidoneSchizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively [L1212, L1213]. Risperidone inhibits dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. It is also said to block histamine receptors, and other neural receptors which are currently being studied [L1213, A1115]. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors [L1212, L1213, A1115].
DB00246ZiprasidoneZiprasidone (marketed as Geodon, Zeldox) is an atypical antipsychotic and gained FDA approval in 2001. Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia. It may also be used to treat Bipolar I disorder as monotherapy for the acute treatment of manic or mixed episodes, or as adjunctive therapy along with lithium or valproate for maintenance. The intramuscular injection of ziprasidone is approved for acute agitation in schizophrenia. [FDA Label]
DrugDrug NameTargetType
DB01238AripiprazoleD(2) dopamine receptortarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Atarget
DB01238Aripiprazole5-hydroxytryptamine receptor 2Atarget
DB01238AripiprazoleCytochrome P450 3A4enzyme
DB01238AripiprazoleCytochrome P450 2D6enzyme
DB01238Aripiprazole5-hydroxytryptamine receptor 1Btarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Dtarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Etarget
DB01238AripiprazoleD(1A) dopamine receptortarget
DB01238AripiprazoleD(1B) dopamine receptortarget
DB01238AripiprazoleD(3) dopamine receptortarget
DB01238AripiprazoleD(4) dopamine receptortarget
DB01238Aripiprazole5-hydroxytryptamine receptor 2Ctarget
DB01238Aripiprazole5-hydroxytryptamine receptor 3Atarget
DB01238Aripiprazole5-hydroxytryptamine receptor 6target
DB01238Aripiprazole5-hydroxytryptamine receptor 7target
DB01238AripiprazoleHistamine H1 receptortarget
DB01238AripiprazoleAlpha-1A adrenergic receptortarget
DB01238AripiprazoleAlpha-1B adrenergic receptortarget
DB01238AripiprazoleAlpha-2A adrenergic receptortarget
DB01238AripiprazoleAlpha-2B adrenergic receptortarget
DB01238AripiprazoleAlpha-2C adrenergic receptortarget
DB01238AripiprazoleMuscarinic acetylcholine receptor M1target
DB01238AripiprazoleMuscarinic acetylcholine receptor M2target
DB01238AripiprazoleMuscarinic acetylcholine receptor M3target
DB01238AripiprazoleMuscarinic acetylcholine receptor M4target
DB01238AripiprazoleMuscarinic acetylcholine receptor M5target
DB01238AripiprazoleCytochrome P450 3A5enzyme
DB01238AripiprazoleCytochrome P450 3A7enzyme
DB01238AripiprazoleSerum albumincarrier
DB06216Asenapine5-hydroxytryptamine receptor 1Atarget
DB06216Asenapine5-hydroxytryptamine receptor 1Btarget
DB06216Asenapine5-hydroxytryptamine receptor 2Atarget
DB06216Asenapine5-hydroxytryptamine receptor 2Btarget
DB06216Asenapine5-hydroxytryptamine receptor 2Ctarget
DB06216Asenapine5-hydroxytryptamine receptor 6target
DB06216Asenapine5-hydroxytryptamine receptor 7target
DB06216AsenapineAlpha-2A adrenergic receptortarget
DB06216AsenapineAlpha-2B adrenergic receptortarget
DB06216AsenapineAlpha-2C adrenergic receptortarget
DB06216AsenapineAlpha-1A adrenergic receptortarget
DB06216AsenapineD(1A) dopamine receptortarget
DB06216AsenapineD(2) dopamine receptortarget
DB06216AsenapineD(3) dopamine receptortarget
DB06216AsenapineD(4) dopamine receptortarget
DB06216AsenapineHistamine H1 receptortarget
DB06216AsenapineHistamine H2 receptortarget
DB06216AsenapineCytochrome P450 1A2enzyme
DB06216AsenapineCytochrome P450 2D6enzyme
DB06216Asenapine5-hydroxytryptamine receptor 5Atarget
DB06216AsenapineUDP-glucuronosyltransferase 1-4enzyme
DB06216AsenapineCytochrome P450 3A4enzyme
DB06216AsenapineBeta-1 adrenergic receptortarget
DB06216AsenapineBeta-2 adrenergic receptortarget
DB00564CarbamazepineSodium channel protein type 5 subunit alphatarget
DB00564CarbamazepineCytochrome P450 2C8enzyme
DB00564CarbamazepineCytochrome P450 2B6enzyme
DB00564CarbamazepineCytochrome P450 3A4enzyme
DB00564CarbamazepineCytochrome P450 1A2enzyme
DB00564CarbamazepineCytochrome P450 2C19enzyme
DB00564CarbamazepineCytochrome P450 2C9enzyme
DB00564CarbamazepineMultidrug resistance protein 1transporter
DB00564CarbamazepineCytochrome P450 3A5enzyme
DB00564CarbamazepineCytochrome P450 3A7enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 2B7enzyme
DB00564CarbamazepineRalA-binding protein 1transporter
DB00564CarbamazepineCanalicular multispecific organic anion transporter 1transporter
DB00564CarbamazepineNeuronal acetylcholine receptor subunit alpha-4target
DB00564CarbamazepineNeuronal acetylcholine receptor subunit beta-2target
DB00564CarbamazepineNuclear receptor subfamily 1 group I member 2target
DB00564CarbamazepineUDP-glucuronosyltransferase 1-1enzyme
DB00564CarbamazepineThyroxine-binding globulincarrier
DB06016CariprazineD(3) dopamine receptortarget
DB06016CariprazineD(2) dopamine receptortarget
DB06016CariprazineCytochrome P450 3A4enzyme
DB06016CariprazineCytochrome P450 2D6enzyme
DB06016Cariprazine5-hydroxytryptamine receptor 1Atarget
DB06016Cariprazine5-hydroxytryptamine receptor 2Btarget
DB06016Cariprazine5-hydroxytryptamine receptor 2Atarget
DB06016CariprazineHistamine H1 receptortarget
DB01068ClonazepamTranslocator proteintarget
DB01068ClonazepamCytochrome P450 3A4enzyme
DB01068ClonazepamSerum albumincarrier
DB01068ClonazepamCytochrome P450 2E1enzyme
DB01068ClonazepamArylamine N-acetyltransferase 2enzyme
DB01068ClonazepamGABA-A receptor (anion channel)target
DB01068ClonazepamNuclear receptor subfamily 1 group I member 2target
DB00334OlanzapineD(1A) dopamine receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M1target
DB00334OlanzapineMuscarinic acetylcholine receptor M3target
DB00334Olanzapine5-hydroxytryptamine receptor 2Atarget
DB00334OlanzapineD(4) dopamine receptortarget
DB00334OlanzapineHistamine H1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M4target
DB00334OlanzapineMuscarinic acetylcholine receptor M2target
DB00334OlanzapineD(2) dopamine receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 2Ctarget
DB00334OlanzapineD(3) dopamine receptortarget
DB00334OlanzapineAlpha-1B adrenergic receptortarget
DB00334OlanzapineCytochrome P450 1A2enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 3Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 6target
DB00334OlanzapineAlpha-1A adrenergic receptortarget
DB00334OlanzapineD(1B) dopamine receptortarget
DB00334OlanzapineSerum albumincarrier
DB00334OlanzapineAlpha-1-acid glycoprotein 1carrier
DB00334OlanzapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00334OlanzapineCytochrome P450 2D6enzyme
DB00334OlanzapineMultidrug resistance protein 1transporter
DB00334OlanzapineCytochrome P450 2C19enzyme
DB00334OlanzapineCytochrome P450 3A4enzyme
DB00334OlanzapineD(1) dopamine receptortarget
DB00334OlanzapineBeta adrenergic receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 1target
DB00334OlanzapineGABA-A receptor (benzodiazepine site)target
DB00334OlanzapineCytochrome P450 2C9enzyme
DB00334OlanzapineUDP-glucuronosyltransferase 1-4enzyme
DB01224Quetiapine5-hydroxytryptamine receptor 2Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 2Ctarget
DB01224QuetiapineD(2) dopamine receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Atarget
DB01224QuetiapineHistamine H1 receptortarget
DB01224QuetiapineCytochrome P450 3A4enzyme
DB01224QuetiapineAlpha-1A adrenergic receptortarget
DB01224QuetiapineAlpha-1B adrenergic receptortarget
DB01224QuetiapineAlpha-1D adrenergic receptortarget
DB01224QuetiapineAlpha-2A adrenergic receptortarget
DB01224QuetiapineAlpha-2B adrenergic receptortarget
DB01224QuetiapineAlpha-2C adrenergic receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Dtarget
DB01224QuetiapineMuscarinic acetylcholine receptor M1target
DB01224QuetiapineMuscarinic acetylcholine receptor M2target
DB01224QuetiapineMuscarinic acetylcholine receptor M3target
DB01224QuetiapineMuscarinic acetylcholine receptor M4target
DB01224QuetiapineMuscarinic acetylcholine receptor M5target
DB01224Quetiapine5-hydroxytryptamine receptor 1Btarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Etarget
DB01224Quetiapine5-hydroxytryptamine receptor 3Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 6target
DB01224Quetiapine5-hydroxytryptamine receptor 7target
DB01224QuetiapineD(1B) dopamine receptortarget
DB01224QuetiapineD(1A) dopamine receptortarget
DB01224QuetiapineD(3) dopamine receptortarget
DB01224QuetiapineD(4) dopamine receptortarget
DB01224QuetiapineCytochrome P450 3A5enzyme
DB01224QuetiapineCytochrome P450 3A7enzyme
DB01224QuetiapineMultidrug resistance protein 1transporter
DB01224QuetiapineCytochrome P450 2C19enzyme
DB01224QuetiapineCytochrome P450 2D6enzyme
DB00734RisperidoneHistamine H1 receptortarget
DB00734RisperidoneD(2) dopamine receptortarget
DB00734RisperidoneAlpha-1A adrenergic receptortarget
DB00734Risperidone5-hydroxytryptamine receptor 2Atarget
DB00734RisperidoneAlpha-1B adrenergic receptortarget
DB00734RisperidoneCytochrome P450 2D6enzyme
DB00734RisperidoneD(1A) dopamine receptortarget
DB00734RisperidoneAlpha-2A adrenergic receptortarget
DB00734RisperidoneAlpha-2B adrenergic receptortarget
DB00734RisperidoneAlpha-2C adrenergic receptortarget
DB00734Risperidone5-hydroxytryptamine receptor 1Atarget
DB00734Risperidone5-hydroxytryptamine receptor 1Dtarget
DB00734Risperidone5-hydroxytryptamine receptor 2Ctarget
DB00734RisperidoneD(3) dopamine receptortarget
DB00734RisperidoneD(4) dopamine receptortarget
DB00734RisperidoneCytochrome P450 3A4enzyme
DB00734RisperidoneCytochrome P450 3A5enzyme
DB00734RisperidoneCytochrome P450 3A7enzyme
DB00734Risperidone5-hydroxytryptamine receptor 7target
DB00734RisperidoneMultidrug resistance protein 1transporter
DB00246ZiprasidoneAlpha-1A adrenergic receptortarget
DB00246ZiprasidoneD(2) dopamine receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 2Ctarget
DB00246ZiprasidoneD(3) dopamine receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 1Atarget
DB00246Ziprasidone5-hydroxytryptamine receptor 1Dtarget
DB00246ZiprasidoneHistamine H1 receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 2Atarget
DB00246ZiprasidoneD(4) dopamine receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 7target
DB00246ZiprasidoneCytochrome P450 3A4enzyme
DB00246ZiprasidoneAlpha-2A adrenergic receptortarget
DB00246ZiprasidoneAlpha-1B adrenergic receptortarget
DB00246ZiprasidoneAlpha-2B adrenergic receptortarget
DB00246ZiprasidoneAlpha-2C adrenergic receptortarget
DB00246ZiprasidoneD(1A) dopamine receptortarget
DB00246ZiprasidoneD(1B) dopamine receptortarget
DB00246ZiprasidoneMuscarinic acetylcholine receptor M1target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M2target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M3target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M4target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M5target
DB00246Ziprasidone5-hydroxytryptamine receptor 1Btarget
DB00246Ziprasidone5-hydroxytryptamine receptor 1Etarget
DB00246Ziprasidone5-hydroxytryptamine receptor 3Atarget
DB00246Ziprasidone5-hydroxytryptamine receptor 6target
DB00246ZiprasidoneAldehyde oxidaseenzyme
DrugDrug NamePhaseStatusCount